Hospital outcomes for patients with pulmonary arterial hypertension in sepsis and septic shock

• Published in: BMC pulmonary medicine 2022-10, Vol.22 (1), p.1-374, Article 374
• Main Authors: Vasudeva, Rhythm, Challa, Abhiram, Tuck, Nicholas, Pothuru, Suveeenkrishna, Vindhyal, Mohinder
• Format: Article
• Language: English
• Subjects: Analysis; Cardiac arrhythmia; Cardiovascular disease; Care and treatment; Cerebral infarction; Chronic illnesses; Clinical outcomes; Complications and side effects; Congestive heart failure; Coronary artery; Coronary artery disease; Coronary vessels; Diabetes; Diabetes mellitus (non-insulin dependent); Diagnosis; Heart attacks; Heart failure; Hospital; Hospital care; Hospital costs; Hospitalization; Hypertension; Kidneys; Length of stay; Lung diseases; Medical care, Cost of; Medical prognosis; Morbidity; Mortality; Myocardial infarction; Outcomes; Patient outcomes; Patients; Pulmonary arteries; Pulmonary hypertension; Pulmonology; Renal failure; Sepsis; Septic shock; Stroke; Vein & artery diseases
• ISSN: 1471-2466; 1471-2466
• DOI: 10.1186/s12890-022-02145-1

Background Pulmonary arterial hypertension (PAH) is associated with increased morbidity and mortality risk. The risk for adverse outcomes in patients with PAH in sepsis or septic shock (SSS) is uncertain. Methods Adult patients diagnosed with SSS were identified in the National Readmissions Database over the years 2016-2017. A 2:1 ratio nearest propensity matching method was employed for several demographic, social, and clinical variables. In-hospital outcomes were compared between patients with PAH and those without, using t-test and chi-squared test as appropriate. Patients with cardiogenic shock were excluded. Relevant ICD-10 codes were used, and statistical significance was set at 0.05. Results A total of 1,134 patients with PAH and sepsis/septic shock were identified, with a mean age of 65 years and 67% identifying as females. Patients with PAH had a higher prevalence of some chronic conditions, including chronic pulmonary disease, renal failure, congestive heart failure, coronary artery disease, obesity, coagulation disease. The prevalence of type 2 diabetes mellitus and alcohol use was lower in this cohort. After matching, patients with PAH and SSS, when compared to those with SSS and without PAH, had an increased occurrence of acute heart failure (24.1% vs. 19.6%, p = 0.003), amongst clinical outcomes. The differences in the occurrence of death, vasopressor use, paroxysmal atrial fibrillation, acute myocardial infarction, acute kidney injury, and stroke outcomes were not statistically different between the two groups. Patients with PAH, however, had a longer hospital stay (13.5 days vs. 10.9 days, p < 0.001) and hospital costs ($164,252 vs. $129,185, p < 0.001). Conclusion Patients with PAH have worse outcomes for acute heart failure in sepsis or septic shock. Other mortality and morbidity outcomes are not statistically different. PAH is also associated with a longer hospital stay and increased hospital costs. These findings should be interpreted recognizing the inclusion of patients with re-admissions and the administrative nature of the database. Keywords: Pulmonary hypertension, Sepsis, Septic shock, Hospital, Outcomes, Mortality